[go: up one dir, main page]

MX2018009696A - Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos. - Google Patents

Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos.

Info

Publication number
MX2018009696A
MX2018009696A MX2018009696A MX2018009696A MX2018009696A MX 2018009696 A MX2018009696 A MX 2018009696A MX 2018009696 A MX2018009696 A MX 2018009696A MX 2018009696 A MX2018009696 A MX 2018009696A MX 2018009696 A MX2018009696 A MX 2018009696A
Authority
MX
Mexico
Prior art keywords
rrcitaa
qrcitaa
citrullinated
polypeptide antibodies
hla polypeptide
Prior art date
Application number
MX2018009696A
Other languages
English (en)
Inventor
Leslie Mobley James
Original Assignee
Cayman Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Co Inc filed Critical Cayman Chemical Co Inc
Publication of MX2018009696A publication Critical patent/MX2018009696A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención hace referencia a métodos para tratar una enfermedad autoinmunitaria en un sujeto humano mediada por la presencia de un epítopo citrulinado QKCitAA, QRCitAA o RRCitAA en el sujeto, donde el método comprende administrar una cantidad con eficacia terapéutica de un anticuerpo o un fragmento de unión especifica de este que se una específicamente al epítopo citrulinado QKCitAA, QRCitAA o RRCitAA. Los aspectos adicionales de la invención incluyen un anticuerpo o un fragmento de unión especifica de este, que se une específicamente a un epítopo citrulinado humano QKCitAA, QRCitAA o RRCitAA.
MX2018009696A 2016-02-10 2017-02-10 Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos. MX2018009696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293621P 2016-02-10 2016-02-10
PCT/US2017/017373 WO2017139577A1 (en) 2016-02-10 2017-02-10 Anti-citrullinated hla polypeptide antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018009696A true MX2018009696A (es) 2018-11-09

Family

ID=59563430

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009696A MX2018009696A (es) 2016-02-10 2017-02-10 Anticuerpos contra polipeptidos del antigeno leucocitario mano (hla) citrulinados y usos de estos.

Country Status (14)

Country Link
US (1) US20190048086A1 (es)
EP (1) EP3413905A4 (es)
JP (1) JP2019508415A (es)
KR (1) KR20180105710A (es)
CN (1) CN108883151A (es)
AU (1) AU2017217814A1 (es)
BR (1) BR112018016383A2 (es)
CA (1) CA3014079A1 (es)
EA (1) EA201891800A1 (es)
IL (1) IL260994A (es)
MX (1) MX2018009696A (es)
PH (1) PH12018501674A1 (es)
SG (1) SG11201806696WA (es)
WO (1) WO2017139577A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866512B2 (en) 2017-11-22 2024-01-09 Vacara Ab Antibodies to citrullinated proteins
CA3129624A1 (en) * 2019-02-15 2020-08-20 Inova Diagnostics, Inc. Compositions and methods for diagnosing and assessing rheumatoid arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562943B1 (en) * 1999-04-21 2003-05-13 Zycos, Inc. Peptide epitopes recognized by disease promoting CD4+ T lymphocytes
EP1603937A2 (en) * 2003-03-07 2005-12-14 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
CA2676185C (en) * 2006-12-26 2013-03-12 Centro De Inmunologia Molecular Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
CN104011068A (zh) * 2011-10-21 2014-08-27 奥古雷克斯生命科学公司 衍生自瓜氨酸化的14-3-3的抗原及其在风湿性关节炎诊断中的用途
HK1203561A1 (en) * 2012-01-19 2015-10-30 医用蛋白国际有限责任公司 Stabilization of the anti-cd20 antibody rituximab

Also Published As

Publication number Publication date
CA3014079A1 (en) 2017-08-17
KR20180105710A (ko) 2018-09-28
PH12018501674A1 (en) 2019-06-10
IL260994A (en) 2018-10-31
SG11201806696WA (en) 2018-09-27
US20190048086A1 (en) 2019-02-14
CN108883151A (zh) 2018-11-23
EP3413905A4 (en) 2019-07-24
WO2017139577A1 (en) 2017-08-17
JP2019508415A (ja) 2019-03-28
BR112018016383A2 (pt) 2018-12-18
EP3413905A1 (en) 2018-12-19
EA201891800A1 (ru) 2019-01-31
AU2017217814A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
MY185813A (en) Factor xi antibodies and methods of use
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2017001138A (es) Metodo.
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
MY184189A (en) Methods of treating nail and scalp psoriasis
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MY201301A (en) Glucagon receptor binding proteins and methods of use thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.